Literature DB >> 32214704

Bioinformatical study on the proteomics and evolution of SARS-CoV.

Shuqun Liu1, Tao Guo1, Xinglai Ji1, Zhirong Sun1.   

Abstract

A novel coronavirus has been identified as the causative agent of the severe acute respiratory syndrome (SARS). For all the SARS-CoV associated proteins derivated from the SARS-CoV genome, the physiochemical properties such as the molecular weight, isoelectric point and extinction coefficient of each protein were calculated. The transmembrane segments and subcellular localization (SubLocation) prediction and conserved protein motifs search against database were employed to analyze the function of SARS-CoV proteins. Also, the homology protein sequence alignment and evolutionary distance matrix calculation between SARS-CoV associated proteins and the corresponding proteins of other coronaviruses were employed to identify the classification and phylogenetic relationship between SARS-CoV and other coronaviruses. The results showed that SARS-CoV is a novel coronavirus which is different from any of the three previously known groups of coronviruses, but it is closer to Bo-CoV and MHV than to other coronaviruses. This study is in aid of experimental determination of SARS-CoV proteomics and the development of antiviral vaccine. © Science in China Press 2003.

Entities:  

Keywords:  SARS; SARS-CoV; conserved protein motif; evolution; sequence alignment

Year:  2003        PMID: 32214704      PMCID: PMC7089238          DOI: 10.1007/BF03184163

Source DB:  PubMed          Journal:  Chin Sci Bull        ISSN: 1001-6538


  2 in total

1.  Structural similarity between HIV-1 gp41 and SARS-CoV S2 proteins suggests an analogous membrane fusion mechanism.

Authors:  Xue Wu Zhang; Yee Leng Yap
Journal:  Theochem       Date:  2004-04-02

2.  The 3D structure analysis of SARS-CoV S1 protein reveals a link to influenza virus neuraminidase and implications for drug and antibody discovery.

Authors:  Xue Wu Zhang; Yee Leng Yap
Journal:  Theochem       Date:  2004-07-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.